UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Discovery of a 9‑mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide

Journal of medicinal chemistry, 2016-04, Vol.59 (7), p.2918-2927

2016

Volltextzugriff (PDF)

Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model

Breast cancer research : BCR, 2019-01, Vol.21 (1), p.9-9, Article 9

2019

Volltextzugriff (PDF)

Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors

Clinical cancer research, 2021-05, Vol.27 (10), p.2755-2763

2021

Volltextzugriff (PDF)

Ionizing radiation abrogates the pro-tumorigenic capacity of cancer-associated fibroblasts co-implanted in xenografts

Scientific reports, 2017-04, Vol.7 (1), p.46714-46714, Article 46714

2017

Volltextzugriff (PDF)

The Cytolytic Amphipathic β(2,2)-Amino Acid LTX-401 Induces DAMP Release in Melanoma Cells and Causes Complete Regression of B16 Melanoma

PloS one, 2016, Vol.11 (2), p.e0148980-e0148980

2016

Volltextzugriff (PDF)

Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model

Oncoimmunology, 2017-01, Vol.6 (8), p.e1338236-e1338236

2017

Volltextzugriff (PDF)

Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2014-06, Vol.63 (6), p.601-613

2014

Volltextzugriff (PDF)

Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer

Scientific reports, 2021-03, Vol.11 (1), p.6731-6731, Article 6731

2021

Volltextzugriff (PDF)

LTX-315 (Oncopore™): A short synthetic anticancer peptide and novel immunotherapeutic agent

Oncoimmunology, 2014-06, Vol.3 (6), p.e29181-e29181

2014

Volltextzugriff (PDF)

LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma

Oncoimmunology, 2024-12, Vol.13 (1), p.2290900-2290900

2024

Volltextzugriff (PDF)

Therapeutic vaccination against a murine lymphoma by intratumoral injection of a cationic anticancer peptide

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010-08, Vol.59 (8), p.1285-1294

2010

Volltextzugriff (PDF)

Cancer-associated fibroblasts from lung tumors maintain their immunosuppressive abilities after high-dose irradiation

Frontiers in oncology, 2015, Vol.5, p.87-87

2015

Volltextzugriff (PDF)

The Novel Oncolytic Compound LTX-401 Induces Antitumor Immune Responses in Experimental Hepatocellular Carcinoma

Molecular therapy. Oncolytics, 2019-09, Vol.14, p.139-148

2019

Volltextzugriff (PDF)

Intratumoral treatment of one tumor lesion with LTX-315 induces complete tumor regression and long-term specific protective immune responses in a metastatic rodent tumor model

Journal for immunotherapy of cancer, 2014-11, Vol.2 (Suppl 3), p.P236-P236

2014

Volltextzugriff (PDF)

LTX-315: a first-in-class oncolytic peptide that reprograms the tumor microenvironment

Future medicinal chemistry, 2017-08, Vol.9 (12), p.1339-1344

2017

Volltextzugriff (PDF)

Abstract 3274: LTX-401 as a novel antitumor and immunotherapeutic agent in an experimental liver cancer model

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3274-3274

2019

Volltextzugriff (PDF)

Abstract 4283: Anticancer effects obtained against A20 lymphomas following treatment with LTX-315 (Oncopore®) in combination with low-dose cyclophosphamide

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.4283-4283

2015

Volltextzugriff (PDF)

Abstract 11: The oncolytic peptide LTX-315 enhances T cell clonality and induces synergy with chemotherapy

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.11-11

2017

Volltextzugriff (PDF)

Abstract 5209: Ionizing radiation abrogates pro-tumorigenic effects from cancer-associated fibroblasts in xenografts

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.5209-5209

2017

Volltextzugriff (PDF)

Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer

Scientific reports, 2021

2021

Volltextzugriff (PDF)

Abstract 4705: The novel oncolytic peptide, DTT-304, induces regression of colorectal cancer tumors in vivo

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4705-4705

2018

Volltextzugriff (PDF)

Abstract 328: Antitumor activity of the oncolytic peptide LTX-315 in syngeneic tumor models

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.328-328

2016

Volltextzugriff (PDF)

Abstract 2347: The amphiphatic β(2,2)-amino acid derivative, LTX-401 induces complete regression of experimental hepatocellular carcinomas

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2347-2347

2016

Volltextzugriff (PDF)

Abstract 3543: Complete regression of solid B16F1 melanoma tumors obtained by intratumoral injection of LTX-315 (Oncopore®)

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.3543-3543

2012

Volltextzugriff (PDF)

The Cytolytic Amphipathic [beta](2,2)-Amino Acid LTX-401 Induces DAMP Release in Melanoma Cells and Causes Complete Regression of B16 Melanoma

PloS one, 2016-02, Vol.11 (2)

2016

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(35)

Sprache

Englisch
(32)
Norwegisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Discovery of a 9‑mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide

Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model

Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors

Ionizing radiation abrogates the pro-tumorigenic capacity of cancer-associated fibroblasts co-implanted in xenografts

The Cytolytic Amphipathic β(2,2)-Amino Acid LTX-401 Induces DAMP Release in Melanoma Cells and Causes Complete Regression of B16 Melanoma

Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model

Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315

Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer

LTX-315 (Oncopore™): A short synthetic anticancer peptide and novel immunotherapeutic agent

LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma

Therapeutic vaccination against a murine lymphoma by intratumoral injection of a cationic anticancer peptide

Cancer-associated fibroblasts from lung tumors maintain their immunosuppressive abilities after high-dose irradiation

The Novel Oncolytic Compound LTX-401 Induces Antitumor Immune Responses in Experimental Hepatocellular Carcinoma

Intratumoral treatment of one tumor lesion with LTX-315 induces complete tumor regression and long-term specific protective immune responses in a metastatic rodent tumor model

LTX-315: a first-in-class oncolytic peptide that reprograms the tumor microenvironment

Abstract 3274: LTX-401 as a novel antitumor and immunotherapeutic agent in an experimental liver cancer model

Abstract 4283: Anticancer effects obtained against A20 lymphomas following treatment with LTX-315 (Oncopore®) in combination with low-dose cyclophosphamide

Abstract 11: The oncolytic peptide LTX-315 enhances T cell clonality and induces synergy with chemotherapy

Abstract 5209: Ionizing radiation abrogates pro-tumorigenic effects from cancer-associated fibroblasts in xenografts

Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer

Abstract 4705: The novel oncolytic peptide, DTT-304, induces regression of colorectal cancer tumors in vivo

Abstract 328: Antitumor activity of the oncolytic peptide LTX-315 in syngeneic tumor models

Abstract 2347: The amphiphatic β(2,2)-amino acid derivative, LTX-401 induces complete regression of experimental hepatocellular carcinomas

Abstract 3543: Complete regression of solid B16F1 melanoma tumors obtained by intratumoral injection of LTX-315 (Oncopore®)

The Cytolytic Amphipathic [beta](2,2)-Amino Acid LTX-401 Induces DAMP Release in Melanoma Cells and Causes Complete Regression of B16 Melanoma

Suchergebnisse filtern